ClinicalTrials.gg
RecruitingNCT07406633Updated Aug 10, 2026

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

A Phase 2 interventional study of KQB198 and Imatinib (Gleevec) in GIST - Gastrointestinal Stromal Tumor, GIST and GIST Metastatic Cancer, sponsored by Kumquat Biosciences Inc.. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Kumquat Biosciences Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing imatinib in Gastrointestinal Stromal Tumors — 8 open to participants now, 9 under way, 2 of them phase 3. imatinib · Gastrointestinal Stromal Tumors.

Planned enrollment
31st of 50
46 · median 56
Started
2026
with 2 others
Phase 2
25 of 50
5 open now
Registered
49th of 50
by date

Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, this one is the 31st largest by planned enrollment, is one of 3 that started in 2026, is one of 25 in phase 2, and was the 49th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

8 of the 50 studies testing imatinib in Gastrointestinal Stromal Tumors are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing imatinib in Gastrointestinal Stromal Tumors, or all of them as a file.
02

Study summary

This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.

03

Conditions studied

  • GIST - Gastrointestinal Stromal Tumor
  • GIST
  • GIST Metastatic Cancer
  • Gastro Intestinal Stromal Tumour
  • Gastrointestinal Tumors

Keywords

  • KQB198
  • imatinib
  • gleevec
  • gist
  • gastrointestinal stromal tumor
  • gastro intestinal stromal tumor
  • gist first line
  • gist 1st line
  • KQB198-103
  • SynerGIST
  • SynerGIST-1
  • SynerGIST-1st
  • SynerGIST-1st Line
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  • Unresectable or disease
  • Tissue confirmation of GIST
  • Valid results from local testing of blood or tumor tissue documenting the presence of a KIT mutation (must not have exon 9 mutation) or PDGFRA mutation (must not have PDGFRA D842V).
  • per v1.1.
  • Patients must be in of treatment for advanced or metastatic disease. Prior imatinib is allowed in or neoadjuvant setting, as long as imatinib was stopped over 1 year ago.
  • Adequate organ function and performance status

Exclusion criteria

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

  • Unable to swallow or GI condition that prevents absorption.
  • Other active within the last 2 years.
  • History of to any component of KQB198 or imatinib.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    KQB198 in Combination with Imatinib

    Drug: KQB198 · Drug: Imatinib (Gleevec)

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Evaluate efficacy of study treatment, as measured by Objective Response Rate (ORR) using Response Evaluation Criteria in Gastrointestinal Stromal Tumors (GIST). Objective response is the proportion of subjects that experience confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 during the time period from 1st dose of study treatment until last dose.

    Time frame: 30 months

Secondary outcomes

  1. Duration of response (DOR)

    Duration of response defined as the time from date of the first documentation of objective tumor response (CR or PR) based on RECIST v1.1 to the first documentation of either PD or death due to any cause, whichever occurs first.

    Time frame: 30 months

  2. Disease control rate (DCR)

    Disease control rate is the proportion of subjects that experience confirmed complete response (CR), partial response (PR), or stable disease based on RECIST v1.1 during the time period from 1st dose of study treatment until last dose.

    Time frame: 30 months

  3. Time to response (TTR)

    Time to response is defined as time from 1st dose of study treatment to date of 1st documentation of objective tumor response (CR or PR) based on RECIST v1.1.

    Time frame: 30 months

  4. Progression-free survival (PFS)

    Progression-free survival is defined as the time from enrollment to the date of Progressive Disease (PD) based on RECIST v1.1 or death due to any cause, whichever occurs first. PFS at 6 months will also be characterized which indicates the proportion of subjects that experience progression within 6 months from time of enrollment.

    Time frame: Up to 30 months

  5. Overall survival (OS)

    Evaluate efficacy of study treatment characterized by OS. Overall survival is defined as the time from start of treatment to death.

    Time frame: Up to 30 months

  6. Number of patients who experience treatment-emergent adverse advents, serious adverse events, and dose-limiting toxicities (Part 1)

    Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs), from first dose of study treatment to 28 days after last dose of study treatment.

    Time frame: From enrollment to the end of treatment

  7. Area under the curve (AUC)

    Area under the concentration-time curve (AUC) of KQB198 in combination with imatinib.

    Time frame: Up to 30 months

  8. Maximum plasma concentration (Cmax)

    Maximum plasma concentration (Cmax) of KQB198 in combination with imatinib.

    Time frame: Up to 30 months

  9. Time to maximum plasma concentration (Tmax)

    Time to maximum plasma concentration (Tmax) of KQB198 in combination with imatinib.

    Time frame: Up to 30 months

07

Study locations

17 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 16 months after the start.

Of 47 phase 2 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Feb 12, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07406633
Lead sponsor
Kumquat Biosciences Inc.
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Jun 23, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Kumquat Clinical Development
Contact
kumquatstudies@kumquatbio.com
858-214-2700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SOS1 Inhibitor MRTX0902 · Imatinib

Start the discussion